Socialiya - Entertainment. Knowledge. Community.
Replimune Gets Third Try at FDA Approval After Makary Departure

Experimental melanoma drug was rejected twice because the agency questioned its study design.

BUSINESS NEWS May 29, 2026

Replimune Gets Third Try at FDA Approval After Makary Departure

Experimental melanoma drug was rejected twice because the agency questioned its study design.

2 views 0 likes 0 comments
Share:
Experimental melanoma drug was rejected twice because the agency questioned its study design.

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya